NASDAQ: KRYSKrystal Biotech Inc Stock
$312.41+2.66 (+0.86%)
Updated Jun 10, 2026
KRYS Price
$312.41
Fair Value Price
$344.38
Market Cap
$9.21B
52 Week Low
$127.99
52 Week High
$320.32
P/E
40.31x
P/B
7.21x
P/S
18.13x
PEG
1.92x
Dividend Yield
N/A
Revenue
$417.30M
Earnings
$225.03M
Gross Margin
94.2%
Operating Margin
49.68%
Profit Margin
53.9%
Debt to Equity
0.09
Operating Cash Flow
$250M
Beta
1.31
Next Earnings
Aug 3, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KRYS Overview
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KRYS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KRYS
Ranked#21 of 462
Ranked#21 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.63 | A | |
| $52.58 | A | |
| $15.66 | A |
Be the first to know about important KRYS news, forecast changes, insider trades & much more!
KRYS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KRYS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRYS ($312.41) is undervalued by 9.28% relative to our estimate of its Fair Value price of $344.38 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KRYS ($312.41) is not significantly undervalued (9.28%) relative to our estimate of its Fair Value price of $344.38 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KRYS ($312.41) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRYS due diligence checks available for Premium users.
Valuation
KRYS fair value
Fair Value of KRYS stock based on Discounted Cash Flow (DCF)
Price
$312.41
Fair Value
$344.38
Undervalued by
9.28%
KRYS ($312.41) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRYS ($312.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRYS ($312.41) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRYS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
40.31x
Industry
18.33x
Market
14.77x
KRYS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
KRYS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
KRYS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.21x
Industry
4.71x
KRYS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRYS price to earnings growth (PEG)
For valuing profitable companies with growth potential
KRYS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
KRYS's financial health
Profit margin
Revenue
$116.4M
Net Income
$55.9M
Profit Margin
48.1%
KRYS's Earnings (EBIT) of $207.32M... subscribe to Premium to read more.
Interest Coverage Financials
KRYS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.4B
Liabilities
$120.2M
Debt to equity
0.09
KRYS's short-term assets ($1.02B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRYS's short-term assets ($1.02B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRYS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KRYS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$80.4M
Investing
-$63.6M
Financing
-$10.5M
KRYS's operating cash flow ($250.28M)... subscribe to Premium to read more.
Debt Coverage Financials
KRYS vs Biotech Stocks
Krystal Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.